GlassScriptPhysician profile
Andrew Gardeck
NPI 1225788144
$5,481.66
in general payments reported to CMS, 2019-2025
9 companies · $2,388 in 2025
The $2,388 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $589 · 2024: $2,505 · 2025: $2,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,442 · Travel and Lodging: $2,023 · Entertainment: $17.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,441.71 |
| Travel and Lodging | $2,022.56 |
| Entertainment | $17.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,889.50 | 2023-2025 | Greenlight Xps, Ams 700, Spaceoar Vue System - 10ml |
| Biotissue Holdings INC. | $929.38 | 2024-2025 | |
| Abbvie INC. | $282.87 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $151.53 | 2024 | Prolaris |
| Axonics, INC. | $102.46 | 2024 | Axonics |
| Merck Sharp & Dohme LLC | $47.60 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Antares Pharma, INC. | $36.87 | 2023 | Nocdurna, Tlando, Xyosted |
| Coloplast Corp | $24.06 | 2025 | |
| Provepharm INC. | $17.39 | 2024 | Bludigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gardeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.